The mentors described their diverse roads into science and research to the second-year students at Ullern Upper Secondary School. Photo: Elisabeth Kirkeng Andersen.

Mentor meeting: many roads to reach your goal

The second-year class of the Researcher Programme at Ullern Upper Secondary School has been assigned new mentors for the school year 2020/2021. The first meeting with the mentors was about how the road to becoming a researcher or doctor or other occupation can be diverse and take many different routes.

This article was originally published in Norwegian on our School Collaboration website.

The students in the second year of the Researcher Programme at Ullern Upper Secondary School are used to having mentors guiding them during the school year, and inspiring and challenging them. This year, all the mentors, except for Øyvind Kongstun Arnesen, are new to the students. These are the mentors:

  • Henrik Sveinsson, a physics researcher at the University of Oslo,
  • Steven Ray Wilson, a chemist and professor at the University of Oslo,
  • Janne Nestvold, laboratory manager at Oslo Cancer Cluster Incubator,
  • Severin Langberg, a PhD student in machine learning and cancer at the Norwegian Cancer Registry (absent from this meeting).

The meeting included introductions of all the mentors and a Q&A session.

Henrik Sveinsson

“I was fascinated by the financial crisis in 2008 and how they used math to cover up the fraud in big banks like Lehman Brothers. I applied to Norway’s Business School in Bergen to study economy, but I learnt quickly that I should have gone to the University of Oslo to study social economics, so I did that instead. Coincidentally, I took up a physics course and became very interested in that, and ended up as a physicist.”

Henrik Sveinsson became interested in the financial crisis of 2008, and how math was used to cover up the economic situation in the big banks that led to the crisis. Photo: Elisabeth Kirkeng Andersen.

Henrik Sveinsson became interested in the financial crisis of 2008 and how math was used to cover up what the big banks were doing. Photo: Elisabeth Kirkeng Andersen.

 

Steven Ray Wilson

Steven studied psychology first, but then switched to chemistry, and is today professor at the Institute for Chemistry at the University of Oslo. He and his students work with pharmaceuticals, drugs and doping, and use chemistry to measure concentration levels in the body.

“Chemistry was the core of everything I thought was cool,” he said to the students of the Researcher Programme about why he chose to study chemistry.

Steven is also a musician, has worked professionally as a musician for periods and even won the Norwegian music award “Spellemanspris”. He encourages the students to have a passion besides their jobs. In one of the research projects he leads, they are cultivating mini-organs to faster test the efficacy and side-effects of drugs, as an alternative to animal testing.

Steven Ray Wilson to the left in the image, tells the students about his experiences from a combined life as a researcher and musician. Photo: Elisabeth Kirkeng Andersen

Steven Ray Wilson (to the left) tells the students about his experiences from combining careers in research and music. Photo: Elisabeth Kirkeng Andersen

 

Øyvind Kongstun Arnesen

Øyvind is a doctor by education, has worked as a surgeon and led the cancer vaccine company Ultimovacs. He tells the students that the road to get there was not always straightforward:

“I dropped out of upper secondary school and went for a long time on unemployment activities as a youth. One of the jobs was to clean test tubes in the laboratory at the Dentist School. After a while, I got more fun assignments and even participated in research into fluor in drinking water, among other things. Then, I finished upper secondary school by picking up some courses and worked at Dikemark as an unskilled worker. That was when I decided to study medicine and retook some subjects to be accepted to the medical programme.

“After that, I worked a lot with developing a vaccine against a contagious form of meningitis at the Norwegian Institute for Public Health. I am very proud to have been a part of that because this vaccine now saves hundreds of thousands of people’s lives.”

Janne Nestvold

Janne manages the research laboratory at Oslo Cancer Cluster Incubator and helps biotech start-ups. She has a PhD in immunology and a background as a cancer researcher at the Institute for Cancer Research, and several other places. Before her career in research, she studied social anthropology and worked with drug addicts in Oslo. That was when she became interested in the combination of drugs and psychology and began to study biology.

Image caption: Janne Nestvold today manages the laboratory in Oslo Cancer Cluster Incubator and has a background in both social anthropology and cancer research. Photo: Elisabeth Kirkeng Andersen.

Janne Nestvold today manages the laboratory in Oslo Cancer Cluster Incubator and has a background in both social anthropology and cancer research. Photo: Elisabeth Kirkeng Andersen.

 


Questions & Answers


Steven, what kind of music do you like – besides your own band?

“To play in a band and be creative is in many ways like being a researcher. Miles Davies is my biggest musical hero. He was extremely innovative and a tough guy unafraid to make any mistakes. When the band played something wrong, the point was to use the mistake to make something completely new in the music.

“Making mistakes is more about how you handle them than anything else. It is about being able to use the imperfect creatively, which I always remember in life, both generally and in research.”

 

Øyvind, how was everyday life when you worked as a surgeon?

“When I worked shifts as a surgeon, they would go on for about 27 hours. We would start at 7:00 am in the morning with a meeting, where we would learn something new. Then, we reviewed all the patients scheduled for surgery that day and assigned the tasks and surgeries among ourselves. The shift team got the easiest surgeries, so we could help the surgeons in the emergency room at Oslo University Hospital when seriously injured patients were admitted. If you were lucky, you got to sleep a little during the night.

“Then, it was the next morning. We had another meeting to report what had happened during the shift, and then we were supposed to visit the patients. I refused to do that, because it is not acceptable for the patients that an exhausted, tired doctor comes in to talk with them.”

The students listened intently to all the advice from their new mentors: Steven, Henrik, Øyvind and Janne. Photo: Elisabeth Kirkeng Andersen.

The students listened intently to all the advice from their new mentors: Steven, Henrik, Øyvind and Janne. Photo: Elisabeth Kirkeng Andersen.

 

Janne, how do you get a reliable result when you perform research?

“Preparations make up half the work. I worked a lot with animal testing, which means you must think through everything before the experiment. For example, the accurate dosage for sick animals and healthy animals. It is very expensive to do these experiments, so it is important that everything is set up correctly. Afterwards, you analyse the results in a research group, and then you publish the results. If others cite your research, it spreads in the environment, and has an impact on other research in the same field.”

 

Question for everyone: why do you want to be our mentors?

Janne: “I want you to know that a career in science is an exciting path to take. Every day you are in the middle of everything here at Oslo Cancer Cluster Innovation Park. There are a lot of opportunities here with the Incubator and the Institute for Cancer Research. I want to show you what some of those opportunities are.”

Steven: “It is fun to follow your journeys. As I told you earlier, I have been a mentor for over 40 students so far, and it is like being in a time machine. In a couple of years, you will do academic and professional things that are amazing, so it is fun to participate and observe and help a little in your lives.”

Henrik: “I am not completely sure, but I accepted the offer immediately. It feels important, when I think it through now, to give you an insight into physics and to contribute to the choices you will make.”

Øyvind: “Some of the most fun things I do are to teach, and I can’t decline when I am the Chairman of Oslo Cancer Cluster (jokingly). Honestly, it is fun for me to contribute as your mentor, so that is the reason.”

 

The mentors gathered with one metre distance apart. From left to right: Steven Ray Wilson, Henrik Sveinsson (behind), Øyvind Kongstun Arnesen (in front) and Janne Nestvold. Photo: Elisabeth Kirkeng Andersen.

The mentors gathered with one-metre distance apart. From left to right: Steven Ray Wilson, Henrik Sveinsson (behind), Øyvind Kongstun Arnesen (in front) and Janne Nestvold. Photo: Elisabeth Kirkeng Andersen.

 

Sign up for our monthly newsletter to see the latest news and events

 

Photo: Stig Jarnes/Oslo Cancer Cluster

More precise cancer treatments with digital solutions

Ketil Widerberg, general manager, Oslo Cancer Cluster.

Ketil Widerberg, general manager of Oslo Cancer Cluster, gives his perspectives on why EHiN and digital health are important for faster development of new cancer treatments in Norway.

 

This interview was first published on EHiN’s website in Norwegian.

 

What do you think are the biggest challenges in the health sector today?

One challenge in cancer treatments is to give the right medicine to the right patient at the right time. This is called precision medicine and means that cancer treatments can to a greater extent be tailored to the individual patient. The government recently proposed more money for this in the State Budget for 2021. There are already digital tools that can identify more targeted treatments ready to be put to use. One example is our member NEC OncoImmunity, who are using artificial intelligence to develop new personalised immunotherapies against cancer.

Another big challenge is to shorten the development time for new cancer medicines. The corona pandemic has shown us that it is possible to quickly develop new treatments, initiate clinical studies and gather data. The analysis of health data will be essential for the development and approval of new treatments. It is important that national infrastructure, such as the Health Analysis Platform, is put in place. One inspiring company is our member Ledidi; their software solution was recently approved for all Covid-19-studies at Oslo University Hospital. This tool can also be used in cancer research to make quick statistical analysis and to cooperate across research groups, hospitals and countries.

A third challenge is how we involve the cancer patient in their own treatment. New technology, for example the data platform from our member Kaiku Health, enables the patients to self-report symptoms in real-time. If we can gather data on pain and side effects every day, instead of every third month, our understanding of cancer improves and the doctor can do a better job.

 

How can you contribute digitally to the health sector?

Oslo Cancer Cluster contributes to the digitalisation of the health sector by connecting pharmaceutical companies and biotech start-ups in cancer with tech companies.

Among other things, we are coordinating the Horizon 2020 EU-project “DIGI-B-CUBE”, which provides funds to collaboration projects between small to medium-sized companies in IT and health. They try to find digital solutions to challenges in the health sector.

Our cluster is also a part of the consortium «NORA EDIH – Norwegian Artificial Intelligence Research Consortium» that was recently selected as one of eight Digital Innovation Hubs that Innovation Norway will recommend to Digital Europe Programme. These innovation centres will be essential to stimulate increased use of digital solutions.

 

How has Covid-19 affected you?

Oslo Cancer Cluster Incubator has put several measures in place to keep laboratories and offices open to ensure that important cancer research and patient treatment can continue as normal during the pandemic. Start-ups, researchers and the incubator have received more support from the financial apparatus for business development, in order to strengthen the health industry in this period of uncertainty. In addition, the Incubator has updated its IT infrastructure to facilitate the increased use of digital solutions from home offices and streaming of meetings and events.

Covid-19 has proven that the health industry is important for society – to fight pandemics, to contribute to better health and to create value. Norwegian companies in health experience great interest from investors now. One example is our member Vaccibody, who signed the largest biotechnology agreement in Norway ever this month and later was listed on Merkur Market (Oslo Stock Exchange), valued at NOK 17 billion.

Covid-19 has also created challenges for cancer patients that missed treatments because of the risk of getting infected and for those who have avoided important health checks because they don’t want to put any extra stress on the health services. Pharma companies experienced a challenge to keep clinical trials running in the beginning of the pandemic, but most hospitals have facilitated this now.

One positive side-effect of the pandemic is that social distancing has led to a rapid digitalisation of the health sector and put digital health at the top of the agenda.

 

What do you expect from EHiN?

EHiN is an arena that connects cross-sectional initiatives in digitalisation and biology across public institutions and private companies. It is a meeting place to find good digital solutions that can be implemented in the health sector and can position Norway internationally in long-term trends, which also creates great value for society.

At EHiN, you will meet different decision makers and participate in setting the political agenda for e-health. We need to continue to stress the importance of good public-private collaboration to develop, test and approve treatments for cancer patients.

 

What else would you like to communicate?

EHiN is important because collaboration is the key to create changes in health. We are working now with an application to become a health catapult centre, in collaboration with several innovation environments in health. If we succeed, we can strengthen the health industry by offering important services to small and medium-sized enterprises in digital health.

We also think it is very positive that the Norwegian Cancer Society have a good collaboration with EHiN. It shows how important e-health in Norway is for the entire cancer community.

 

Meet Ketil Widerberg as he moderates the session “Fremtidsmennesket” on 10 November 2020 at 11:00-12:00 during EHiN 2020. 

Register to EHiN here

 

Sign up for our monthly newsletter to see the latest news and events

Professor Pål Rongved introduced the ZinChel technology that fights antimicrobial resistance at Oslo Life Science Week 2017. Photo: UiO/Terje Heiestad

Norwegian invention to fight antibiotic resistance

Professor Pål Rongved introduced the ZinChel technology that fights microbial resistance at Oslo Life Science Week 2017. Photo: UiO/Terje Heiestad

A new Norwegian technology may help stop the increase of antibiotic multi-resistance.

Antibiotic resistance is growing, and the world is running out of treatment options. In 2020, approximately 700 000 people will die from antibiotic-resistant infections. By 2050, as many as 10 million deaths are forecast.

Increasing numbers of cancer patients also develop resistance to multiple antibiotics, which potentially leads to life-threatening conditions. The World Health Organization (WHO) writes that: “Without effective antibiotics, the success of major surgery and cancer chemotherapy would be compromised.”

A Norwegian solution for global challenge

New Norwegian technology from the start-up Adjutec Pharma may help to stop increasing antibiotic resistance. The technology, known as ZinChel, was first developed in collaboration between the University of Tromsø (UiT) and the research group SYNFAS at the University of Oslo (UiO).

ZinChel has shown promising effects against a group of multi-resistant bacteria, which are increasingly widespread in many regions of the world, including Europe.

The bacteria, known as gram-negative, are equipped with a type of enzyme called “metallo-beta-lactamase”, which renders modern carbapenem antibiotics useless. These bacteria are on the World Health Organization’s list of the 12 most dangerous bacteria in the world, causing severe and often deadly infections.

Pål Rongved is a Professor at the University of Oslo with a PhD in chemistry. He is one of the inventors behind ZinChel and the founder and CEO of the start-up company Adjutec Pharma AS.

Adjutec Pharma AS has a strong momentum to develop the technology further together with our Norwegian partners and private investors. If we do this correctly, the results of this project can provide patients with vital treatment in the future and contribute to the establishment of a health industry that provides new jobs. We have an ethical and moral responsibility to bring the technology to market and patients as quickly as possible. There is no time to lose and we are on track”.

Creating value for patients and industry

The technology is not yet available to treat patients, because it is still in pre-clinical development. This means that it will need to be further tested on animals and humans to assess its safety and efficacy.

Adjutec Pharma has recently secured exclusive rights to the patents for the ZinChel technology and will raise more money to accelerate development of the drugs in collaboration with researchers at University of Oslo.

Adjutec Pharma has received $3 million in grants, including support from the Norwegian Research Council and Novo Nordisk. The company will raise $20 million in investments to reach Phase II clinical trials, including public and private funding.

Adjutec Pharma receives start-up services from Oslo Cancer Cluster (OCC) Incubator, who are partly financed by SIVA, a governmental enterprise facilitating a national infrastructure for innovation.

Bjørn Klem, general manager of Oslo Cancer Cluster Incubator, has provided important help in the establishment of Adjutec Pharma. Photo: Stig Jarnes

Bjørn Klem, general manager of Oslo Cancer Cluster Incubator, has provided important help in the establishment of Adjutec Pharma. Photo: Stig Jarnes

Bjørn Klem, general manager of OCC Incubator, said:

“OCC Incubator provided help and advice to the founders when establishing Adjutec Pharma, including finding competent people for the board. The OCC Incubator has negotiated the licensing agreement with the University of Oslo, which gives the company exclusive rights to commercialise the inventors’ patents. We also help the company with the development of a business strategy and financing through public funding programmes and private investors.”

Sign up to our monthly newsletter

The students from the Researcher Programme were eager to hear more from Vegard Vinje after the mentor meeting. Vegard, in the middle, is a researcher at Simula and former student at Ullern Upper Secondary School. Photo: Elisabeth Kirkeng Andersen.

First-year students met their mentors

This fall, 32 students have begun their first year of the Researcher Programme at Ullern Upper Secondary School. Earlier in October, they met their four mentors, who will support them throughout the school year – and the mentors include some big names in the field.

Thirty-two nervous first-year students are sitting in Jónas Einarsson Auditorium. They are all attending the Researcher Programme. This is a unique opportunity for young people in Oslo who wish to immerse themselves in science, especially in biomedicine, and gain a more practical introduction to subjects like maths, physics, chemistry, biology, and IT and programming.

First of three meetings

Ragni Fet, former cancer researcher and currently biology teacher at Ullern school, is responsible for the first-year students at the Researcher Programme.

“It is nice to see all of you here and it is my pleasure to introduce the four mentors to you,” Fet says.

The mentors are:

  • Vegard Vinje, researcher at Simula and former Ullern student
  • Jónas Einarsson, CEO of Radforsk and initiator of Oslo Cancer Cluster and Oslo Cancer Cluster Innovation Park
  • Simone Mester, PhD student and former Ullern student
  • Bjørn Klem, general manager of Oslo Cancer Cluster Incubator and former Head of Research at Photocure.
The mentors. From left to right: Vegard, Jónas, Simone and Bjørn. Photo: Elisabeth Kirkeng Andersen.

The mentors. From left to right: Vegard, Jónas, Simone and Bjørn. Photo: Elisabeth Kirkeng Andersen.

Fet tells the students that they will meet the four mentors today and twice more during the school year. The next time the visit will take place at one of the mentor’s workplaces. Read more about what the students of the Researcher Programme (2019/2020) experienced when they visited Simone Mester at her workplace in December 2019.

The following time, the students will present their own research to the mentors and receive an evaluation from them. Read more about the type of research the students of the Researcher Programme (2019/2020) presented to their mentors.

“Today you can ask the mentors as many questions you like about their choices concerning education, focus, career, what they have learnt and experienced, and what they are doing today. Please feel free to ask your questions,” Fet says.

Question time

The students are eager to ask their questions to Vegard, Jónas, Simone and Bjørn during the next hour. It is obvious that the students have done some in-depth research on their four mentors.

When the question time was over, Jónas said:

“This was fun! You asked us good and interesting questions. This was both educational and entertaining for me too.”

You can read some of the questions and answers that occurred during the course of the hour they spent together below.

Q&As

Question: What is the most exciting thing you have experienced during your careers?

Vegard:

I was interviewed by NRK radio and they produced an article about our research. The research is about how breathing affects flows in the brain, something that can help to clear the brain from toxins.

An accumulation of toxins in the brain can be associated with an increased risk to develop Alzheimer’s disease, so NRK’s angle was: “Norwegian study: Your breathing can play a part in Alzheimers” even though our research does not say anything about causation. In the comments under the piece, the conclusion was practically “Yoga is good for the brain”, since breathing is an essential part of yoga.

It was interesting to see how our research was communicated so differently from what our work actually was.

The first-year students of the Researcher Programme listened intently to the mentors' stories. Photo: Elisabeth Kirkeng Andersen.

The first-year students of the Researcher Programme listened intently to the mentors’ stories. Photo: Elisabeth Kirkeng Andersen.

Jonas:

My biggest moment was two years ago when I was sitting at a science conference on immunotherapy against cancer in New York. The same day, it was announced that the two researchers Tasuku Honjo and James Allison had been awarded the Nobel Prize in Medicine for their discovery of how checkpoint inhibitors, a form of immunotherapy, can make the body’s own immune system fight cancer.

When the conference opened, Jim – which is James Allison’s nickname – came into the auditorium to give a presentation. This had already been decided long ago and had nothing to do with the Nobel Prize. The whole room stood up and clapped. That was huge. Jim was also here last year and visited the students who are now in the second year of the Researcher Programme.

Simone:

When I was finished with my master I was accepted into SPARK, which is the University of Oslo’s innovation programme. Because of that, I was also invited to Arendalsuka to present my project to many important people, and it was a big thing for me to be able to contribute.

In addition, it is always big when I experience an Eureka! moment in the laboratory: it is fun when you get a result that proves that your theory actually works.

Bjørn:

To find solutions to different things is what I like the most. If I had to choose one individual event, it would have to be this: I had worked for a long time in Photocure as Head of Research, and developed a medical device called Cevira, which is made to treat cervical cancer. We tested it in humans and it had good results, but then it was put on hold for many different reasons.

Then, about one year ago, the news came that a Chinese company had licensed this product for billions of NOK. They are already underway with the last part of the testing of Cevira, so maybe it will enter the market and be used by women all over the world in only a few years. I knew this product would work, so it is fun it is no longer forgotten about.

Question: Where do you think your research careers will take you, Simone and Vegard?

Vegard:

I dream about finding out more about the different flows in the brain that I am doing research on, but I am not sure I will find the answers. It is a simple transition between research and private industry, so maybe I will start my own company in time.

Simone:

I really want to start my own company and it is scary to even say it, but I am already underway. To start a company and develop a pharmaceutical that can make a difference for patients would be fun. I think it is a very exciting and challenging journey, and I am lucky to have guides that help me to do this.

Question: Why are you working with what you are doing now?

Vegard:

When I think back, it seems completely random. I did not have a plan about what I wanted to become when I attended upper secondary school. I liked maths and physics, and got an education in that, which was really fun. When I completed my bachelor degree, I got a summer job at Simula. This was in 2013 and after that, they have continued to offer me work and research projects.

Jónas:

I am a doctor by education and worked for many years as a general practitioner in Western Norway. When I moved from Western Norway to Oslo because of family, I did not have any job to go to and I did not know what I wanted to do either. A friend of mine worked at the Radium Hospital’s Research Foundation and offered me a project-based position for six months so that I could have time to think about the future, and since then I have remained.

Bjørn:

I do not think it is completely random, even if Vegard and Jónas say so, but it seems like that for me too. I studied pharmacy and later I was hired into Photocure and afterwards, I ended up here in the Incubator. But it isn’t completely random. We are affected by our surroundings: just think about what you do here at Ullern and what you are exposed to in the Oslo Cancer Cluster Innovation Park. Even if things seem random sometimes, they are not.

Bjørn Klem tells about his background as a pharmacist. Photo: Elisabeth Kirkeng Andersen.

Bjørn Klem tells the students about his background as a pharmacist. Photo: Elisabeth Kirkeng Andersen.

Jónas:

What you are talking about, Bjørn, is called Serendipity and is a type of unplanned discovery or a positive surprise when looking for something else.

For example, I was a rascal during upper secondary school and I wanted to study medicine, but my grades were not nearly good enough for that. So one day, my brother who was the president of ANSA, the association for Norwegian students who study abroad, called me. He told me that all Icelandic people are accepted to the first year of medical school in Iceland, and since I am an Icelandic citizen, that became my way in. That is typical serendipity.

Simone:

I studied science at Ullern Upper Secondary School and thought medicine would be a safe choice. But I wasn’t really interested of patient care, which made me very unsure. I talked a lot with Ragni, who was my biology teacher, and she encouraged me to study molecular biology at the university.

I was lost and confused the first year, because I wanted to study and work with something that has a value and is of use to others: to make a difference. Luckily, I found the research group led by Jan Terje Andersen and Inger Sandlie, where I have received a lot of support to go my own way and be innovative.

By the way, Inger Sandlie is my role model as a researcher and innovator. She has the most innovations registered with Inven2, the tech transfer office of the University of Oslo and Oslo University Hospital, and is behind Vaccibody, that recently entered Norway’s largest agreement in biotechnology.

Simone and Ragni. Ragni Fet, a former cancer researcher and now biology teacher at Ullern was crucial in Simone’s study choice. Photo: Elisabeth Kirkeng Andersen.

Simone and Ragni. Ragni Fet, a former cancer researcher and now biology teacher at Ullern was crucial in Simone’s decision to study molecular biology. Photo: Elisabeth Kirkeng Andersen.

Articles about previous mentor meetings

 

Sign up for our monthly newsletter to see the latest news and events